Fusion Antibodies Plc engages in research, development, and manufacturing recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The firm also offers antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company was founded by Michael Townsley and James Anthony Johnston on November 29, 2000 and is headquartered in Belfast, the United Kingdom.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company